ArticleBMC cancer2008
Prodrug converting enzyme gene delivery by L. monocytogenes.
Article in BMC cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- Enhancing the Anticancer Activity of AttenuatedACS chemical biology · 2024Article
- Bacterial-Mediated Tumor Therapy: Old Treatment in a New Context.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery.Frontiers in pharmacology · 2019Article
- Tumour-targeting bacteria engineered to fight cancer.Nature reviews. Cancer · 2018Review
- White paper on microbial anti-cancer therapy and prevention.Journal for immunotherapy of cancer · 2018Review
- Bacteria in Cancer Therapy: Renaissance of an Old Concept.International journal of microbiology · 2016Review
- Listeria monocytogenes: a promising vehicle for neonatal vaccination.Human vaccines & immunotherapeutics · 2014Review
- Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.Journal of materials chemistry. B · 2014Article
- Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Frontiers in cellular and infection microbiology · 2014Review
- Single-agent combinatorial cancer therapy.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Specific antibody-receptor interactions trigger InlAB-independent uptake of Listeria monocytogenes into tumor cell lines.BMC microbiology · 2011Article
- Proliferation behavior of E. coli in a three-dimensional in vitro tumor model.Integrative biology : quantitative biosciences from nano to macro · 2011Article
- Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy.Gene therapy · 2011Review
- Promoters with cancer cell-specific activity for melanoma gene therapy.Acta naturae · 2011Article
- Selectivity and efficiency of late transgene expression by transcriptionally targeted oncolytic adenoviruses are dependent on the transgene insertion strategy.Human gene therapy · 2011Article
- Direct injection of functional single-domain antibodies from E. coli into human cells.PloS one · 2010Article
- Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.Journal of biomedicine & biotechnology · 2010Article
- High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.Cancer research · 2009Article
- Biological gene delivery vehicles: beyond viral vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundListeria monocytogenes is a highly versatile bacterial carrier system for introducing protein, DNA and RNA into mammalian cells. The delivery of tumor antigens with the help of this carrier into tumor-bearing animals has been successfully carried out previously and it was recently reported that L. monocytogenes is able to colonize and replicate within solid tumors after local or even systemic injection.
methodsHere we report on the delivery of two prodrug converting enzymes, purine-deoxynucleoside phosphorylase (PNP) and a fusion protein consisting of yeast cytosine deaminase and uracil phosphoribosyl transferase (FCU1) into cancer cells in culture by L. monocytogenes. Transfer of the prodrug converting enzymes was achieved by bacterium mediated transfer of eukaryotic expression plasmids or by secretion of the proteins directly into the host cell cytosol by the infecting bacteria.
resultsThe results indicate that conversion of appropriate prodrugs to toxic drugs in the cancer cells occured after both procedures although L. monocytogenes-mediated bactofection proved to be more efficient than enzyme secretion 4T1, B16 and COS-1 tumor cells. Exchanging the constitutively PCMV-promoter with the melanoma specific P4xTETP-promoter resulted in melanoma cell-specific expression of the prodrug converting enzymes but reduced the efficiencies.
conclusionThese experiments open the way for bacterium mediated tumor specific activation of prodrugs in live animals with tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.